Fortress Biotech, Inc. (NASDAQ:FBIO - Get Free Report) shares crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.75 and traded as high as $1.96. Fortress Biotech shares last traded at $1.89, with a volume of 236,600 shares traded.
Fortress Biotech Stock Performance
The firm has a 50-day moving average price of $1.89 and a 200 day moving average price of $1.75. The firm has a market capitalization of $53.52 million, a PE ratio of -0.81 and a beta of 1.75. The company has a quick ratio of 1.55, a current ratio of 1.72 and a debt-to-equity ratio of 1.74.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. Wolverine Trading LLC purchased a new position in Fortress Biotech in the fourth quarter valued at $26,000. XTX Topco Ltd purchased a new position in Fortress Biotech in the fourth quarter valued at $62,000. Jane Street Group LLC purchased a new position in Fortress Biotech in the fourth quarter valued at $69,000. PFG Investments LLC boosted its holdings in Fortress Biotech by 28.4% in the first quarter. PFG Investments LLC now owns 45,259 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 10,000 shares during the period. Finally, Weaver Consulting Group boosted its holdings in Fortress Biotech by 101.8% in the first quarter. Weaver Consulting Group now owns 46,417 shares of the biopharmaceutical company's stock valued at $72,000 after purchasing an additional 23,419 shares during the period. 96.51% of the stock is currently owned by hedge funds and other institutional investors.
Fortress Biotech Company Profile
(
Get Free Report)
Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.
See Also
Before you consider Fortress Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortress Biotech wasn't on the list.
While Fortress Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
